Antisense oligodeoxyribonucleotides (ODN) targeted against the breakpoint in BCR-ABL mRNA will specifically decrease BCR-ABL mRNA, provided cells are first permeabilised with streptolysin-O (SL-O). We used 18-mer chimeric methylphosphonodiester: phosphodiester linked (4-9-4) ODN complementary to 9 bases either side of the BCR-ABL junction to purge harvests ex vivo in three CML patients who remained completely Ph positive after multiple chemotherapy courses. After CD34
plantation. Long-term follow-up of recipients of unmanipulated autografts suggests a survival advantage, although almost all patients relapse within 12 months of the graft. 1, 2 During recovery from chemotherapy, the PB of some patients may become transiently negative for the Philadelphia (Ph) chromosome, especially if the procedure is performed in the first few months following diagnosis. 3, 4 These cells can be leukapheresed (or BM harvested) during this recovery phase and used to support an autograft. [4] [5] [6] [7] The impact of this approach on disease outcome is currently the subject of prospective randomised studies. However, some patients remain completely Ph positive after priming chemotherapy. It is difficult to see how such patients might be cured by autografting with exclusively Ph-positive cells, and many groups do not transplant such patients.
The Ph translocation creates the novel leukaemia-specific gene, BCR-ABL. Short sequences of DNA which are complementary, or antisense, to the BCR-ABL breakpoint may hybridise specifically to BCR-ABL mRNA, creating a DNA:RNA heterodimer. The ubiquitous intracellular enzyme ribonuclease H (RNase H) will cleave the RNA component of DNA:RNA heteroduplexes. Thus, antisense oligodeoxyribonucleotides (ODN) directed against the BCR-ABL junction may induce the specific cleavage of the BCR-ABL mRNA target, whilst leaving normal BCR and ABL intact.
Natural DNA is held together by phosphodiester (PO) internucleoside linkages. Although PO linkages direct RNase H activity, they are rapidly degraded by nucleases which are present in all biological fluids including intracellular compartments. We have previously shown in a cellfree system that both b2a2 and b3a2 BCR-ABL breakpoint mRNAs were specifically cleaved by RNase H when directed by appropriate 18-mer antisense ODN. The best antisense effector was a structure held together by nine central PO linkages flanked by four nuclease-resistant methylphosphonodiester (MP) linkages. 8 We have also shown that sequence-specific antisense-mediated cleavage can occur in intact cells, but only if ODN entry into the cells is first facilitated by permeabilisation with streptolysin-O (SL-O). 8, 9 SL-O permeabilisation may be used on a scale sufficient to purge fresh or frozen BM or PBSC harvests, without significant toxicity either directly or on subsequent CFU-GM growth, provided harvests are first selected for CD34-positive cells. 10 In the present work, we report the outcome of transplanting autologous stem cells following purging with chimeric MP:PO antisense ODN 18-mers targeted to the BCR-ABL mRNA breakpoint. ODN were delivered to the intracellular compartments using an optimised SL-O reversible permeabilisation technique. Patients were selected for this trial if their PB remained completely Ph positive in the recovery phase following multiple courses of priming chemotherapy. Three patients matched this criterion.
Patients and methods

ODN synthesis
The antisense 18-mer ODNs were targeted to nine bases either side of the BCR-ABL junction. ODN structure comprised nine central PO internucleoside linkages, flanked on 5Ј and 3Ј sides by four MP linkages. ODN sequences complementary to both the b2a2 and b3a2 target were examined. ODN sequence and structure are given in Figure 1 .
ODN were synthesised as previously described, 9 but scaled up to yield quantities sufficient for clinical use. ODN were synthesised on an Applied Biosystems 381A DNA synthesiser (Warrington, Cheshire, UK) using deoxynucleoside cyanoethyl phosphoramidites and methylphosphonamidites supplied by Glen Research (Sterling, VA, USA; UK distributor Cambio, Cambridge, UK). For the initial SL-O optimising in vitro experiments on each patient's harvest (see below), ODN with a 5Ј fluorescein tag but otherwise of the same structure were used ( of Millipore Ltd., Watford, UK), and if fluorescein labelled, also by gel electrophoresis to remove fluoresceinated impurities. ODNs destined for clinical use were processed under aseptic conditions in the Pharmacy Department. The ODN concentration was adjusted to 100 m by dilution in serum-free RPMI 1640 medium (Gibco, Paisley, UK), and the solutions packaged into 1 ml sterile ampoules, each containing 100 nanomoles of ODN. All ODN-containing ampoules were stored at Ϫ20°C in the dark until use.
Patient population and harvesting
The study protocol was approved by the Local Research Ethics Committee, and also by the Medicines Control Agency of the United Kingdom. Clinical details of the three patients entered into the study are given in Table 1 . Each patient had suffered from typical Ph-positive CML for 24, 23 and 19 months, respectively. Each case was treated with ␣-interferon at doses of up to 52, 21, 35 megaunits/m 2 /week, without cytogenetic benefit or adequate haematological control, and had been off interferon for at least 3 months before harvesting was attempted. No patient had significant marrow fibrosis as assessed by standard reticulin staining of a trephine biopsy taken shortly before harvesting. Cytogenetic assessment immediately prior to entry into the study revealed all metaphases to be Ph positive, without evidence of additional chromosomal abnormalities, in all three cases. Each patient was then treated with intensive chemotherapy, using idarubicin 20 mg/m 2 /day i.v. for 2 days and cytosine arabinoside 200 mg/m 2 /day i.v. by continuous infusion for 5 days, as previously described. 4, 11 In all three cases, cytogenetic examination of PB metaphases obtained during the recovery from this therapy remained 100% positive for the Ph chromosome. Each patient received two further courses of cytosine arabinoside alone at a dose of 1.5 g/m 2 twice daily for 3 days, the second of which was followed by lenograstim at a dose of 263 g daily i.v. (until PBSC collection was complete). After each course, all PB metaphases still remained Ph positive.
As the PB white cell count began to rise following recovery from the final course of chemotherapy, PB mononuclear cells were collected using a Cobe Spectra (Gloucester, UK), used in accordance with the manufacturer's instructions. The resultant leucoconcentrate was typically of around 150 ml with a haematocrit of less than 2%. This volume was made up to 500 ml by the addition of calcium and magnes- Table 1 Clinical details of study patients ium-free Dulbecco's phosphate-buffered saline (Life Technologies, Paisley, UK) with 1% Human Albumin Solution (Blood Products Laboratory, Elstree, UK) with added 0.2% trisodium citrate (DPBS-HAS). The leucoconcentrate was then washed twice in DPBS-HAS, using centrifugation at 800 g for 4 min. CD34-positive cells were obtained by processing platelet-depleted washed leucoconcentrates in an Isolex 300 CD34 ϩ cell selection system (Baxter Healthcare, Newbury, UK), in accordance with the manufacturer's instructions. After CD34-positive cell selection was completed, cells were left undisturbed for at least 3 h in DPBS-HAS before further treatment.
streptolysin-O and ODN purging technique
We have previously reported the use of SL-O to enhance ODN uptake in autologous harvests. 10 To control for variation in the bioactivity of different batches of SL-O (Sigma, Poole, UK), each fresh batch was activated for 2 h by 5 mm dithiothreitol, then checked for activity, and frozen in aliquots at Ϫ20°C until required. 12 For each harvest, pilot in vitro experiments were carried out on an aliquot of the harvest to determine the optimal SL-O concentration for ODN purging. 10 5 cells were suspended in 100 l of serum-free RPMI, and exposed at 37°C to: (1) SL-O at varying concentrations of up to 10 units per 10 6 cells, and (2) 20 m of BCR-ABL directed fluorescent ODN, in order to follow cell uptake of ODN. 9 After 10 min incubation at 37°C, SL-O-induced surface membrane pores were resealed by diluting the permeabilisation reaction 10-fold, using 10% FCS in RPMI. The cells were then incubated for a further 30 min at 37°C, with occasional gentle agitation.
After this time, ODN uptake and cell viability were simultaneously assessed by flow cytometry, as previously described. 12 Briefly, 100 l of cell suspension was added to 900 l of RPMI with 10 l of 0.1% propidium iodide (PI). Cell suspensions were then analysed by an Ortho Cytoron Absolute flow cytometer, using a 15 mW argon ion laser set to simultaneously measure PI and fluorescein (ie ODN) uptake. From the cytometer results, the following proportions were calculated for each SL-O concentration: The optimal concentration was defined as the maximal SL-O concentration at which the proportion of non-viable cells did not exceed 10%.
The main harvest was then centrifuged and washed once at 800 g for 10 min in Iscove's medium (Gibco), and resuspended at a concentration of 2 ϫ 10 7 cells/ml. The resuspended cells were aliquoted in 1 ml amounts into 30 mm culture wells (Corning, New York, NY, USA), and SL-O at optimal concentration was added, together with 20 m ODN targeting the appropriate breakpoint. After incubation for 10 min at 37°C in 5% CO 2 , 1 ml of 20% HAS was added to each well in order to reseal SL-O-induced pores, and incubated for a further 60 min. Then, aliquots were taken for CD34-positive cell numbers and CFU-GM estimation, and the remaining harvest was cryopreserved using conventional techniques until required.
CFU-GM assays
CFU-GM assays were carried out by adding 2.5 ml of Iscove's medium, 0.5 ml of bladder carcinoma cell line 5637 conditioned medium, 1 ml of foetal calf serum and 0.5 ml of 3.3% agar to 0.5 ml aliquots of resealed cells. These were incubated at 37°C in 5% CO 2 for 10 days. The numbers of resultant CFU-GM colonies were expressed per 10 5 plated cells.
CFU-GM harvesting and molecular analysis
After at least 12 days in culture, individual CFU-GM colonies were harvested and analysed for their expression of BCR-ABL mRNA as previously described. 11 Briefly, up to 24 individual colonies were plucked, and immediately transferred to sterile microfuge tubes containing 20-40 units of RNase inhibitor (RNasin; Promega, Madison, WI, USA) in lysis buffer (100 mm Tris HCl pH 8.0, 500 mm LiCl, 10 mm EDTA, 1% lithium dodecyl sulphate (LiDS), 5 mm dithiothreitol). mRNA was recovered from the lysed cells using 20 l aliquots of oligo dT-coated paramagnetic beads (Dynal, UK). The mRNAs were reverse transcribed while still attached to the beads, using Moloney murine leukaemia virus reverse transcriptase. All samples were screened for the presence of RT-PCR mRNA by amplification of ␤-ACTIN and ABL mRNA.
The BCR-ABL status was assessed using a nested PCR protocol. In the event of detecting ␤-ACTIN/ABL-positive but BCR-ABL-negative colonies, the BCR-ABL status was checked by repeating the PCR reactions using an alternative set of primers. Full details of the methodology used, including all probe and primer sequences are given in Ref. 11 .
Transplant conditioning and management
Patients were conditioned for transplantation with highdose busulphan, 1 mg/kg recipient weight four times daily on each of days Ϫ6 to Ϫ3 inclusive. Phenytoin prophylaxis was given throughout high-dose busulphan therapy to prevent seizures. The purged graft was infused on day 0; all three grafts were 99% viable on thawing as assessed by Trypan Blue exclusion. Neutrophil engraftment was defined as the first of at least 2 consecutive post-transplant days on which the PB neutrophil count reached or exceeded 0.5 x 10 9 /l. Platelet engraftment was defined similarly, as the time to achieve 20 ϫ 10 9 /l and platelet transfusion independence. Post-transplant growth factors were not used. Cytogenetic analysis of the marrow was carried out 3 months post transplant. Twenty-four of 24 CFU-GM colonies from a CD34 selected but unpurged sample were positive for b2a2 mRNA. NA ϭ not available.
Results
Processing of PBSC collections
A single leukapheresis was carried out on all three patients, yielding 1.1-12.87 ϫ 10 8 mononuclear cells/kg recipient weight. The proportion of CD34-positive cells was 0.94-5.92%, and ranged from 2.92 to 9.23 ϫ 10 6 /kg recipient weight. The yield of CD34 positive cells after CD34-positive cell selection was low, at 22-46%. After ODN purging, CD34-positive cell numbers were lower than the deal for cases 1 and 2 at 0.55 and 0.71 ϫ 10 6 cells/kg recipient weight respectively, with up to 53% cell loss during the ODN purging step (see Table 2 ). Table 2 also gives the molecular status of CFU-GM colonies grown after ODN purging. All colonies grown from the b3a2 breakpoint-positive cases remained BCR-ABL mRNA positive. In contrast, no colonies from the b2a2-positive case remained BCR-ABL positive, even though all 24 colonies from a CD34 selected but unpurged sample from this patient were BCR-ABL positive. Table 3 gives the clinical outcome following transplantation. In the interval between carrying out ODN purging and admission for transplantation, patient 2 progressed to accelerated phase. Both patients 1 and 3 remained in first chronic phase at transplantation. No unexpected clinical problems were encountered, over and above those expected after autografting. Neutrophil engraftment to 0.5 ϫ 10 9 /l was slow, between 25 and 51 days. Platelet engraftment to 20 ϫ 10 9 /l was also slow at 38-144 days. All three patients remained generally well, without symptoms or laboratory findings suggestive of intercurrent viral infection. Patient 2 subsequently developed blast cells in the peripheral blood on day ϩ51 with worsening cytopenias, and marrow examination revealed myeloid blast transformation. The patient declined further intensive chemotherapy, and died on day 91 post transplant. Cytogenetic examination of the marrow Table 3 Clinical outcome following ODN-purged transplantation 
Molecular result of ODN purging
Clinical outcome
Discussion
Several recent authoritative reviews of the treatment of CML have mentioned ex vivo purging by antisense ODN, as a way of improving outcome after autografting. [5] [6] [7] 13 However, the available clinical information on this approach is sparse.
14 Ex vivo purging with C-MYB directed ODN has been reported in abstract form. 14, 15 De Fabritiis et al 16 recently reported eight patients with advanced CML who underwent autografting with cells purged by BCR-ABL directed ODN. Treatment was with phosphorothioate (PS)-linked 26-mer ODN targeted at the BCR-ABL junction. Two of eight patients were transiently Ph negative following the procedure, although both died of their disease at 7 and 30 months post BMT.
We now report three further cases of CML who underwent autografts with cells which had been purged with antisense ODN directed against BCR-ABL. Our purging technique differs from that of de Fabritiis et al 16 in two important respects. Firstly, we used chimeric MP:PO ODN structures which we have previously shown to be superior antisense effectors than comparable all PS-linked ODNs. 8 Secondly, we permeabilised the target cells with SL-O before treating with ODN, since without SL-O permeabilisation we have been consistently unable to demonstrate any reduction in target mRNA. 8, 10, 17 Each of these manoeuvres was introduced in order to improve ODN uptake and/or molecular effect in the target cell population. Despite this, all three patients had cytogenetic evidence of persisting disease by 3 months post transplant. The molecular studies indicate that following ODN purging in b3a2-positive cases, all CFU-GM remain leukaemic, while in the b2a2-positive patient, no CFU-GM were positive. It is not clear from the present data whether this difference is due to a true antisense effect. The b2a2 BCR-ABL junction may be more accessible to ODN than the b3a2 junction. 8, 18 However, some CML progenitors may be transcriptionally silent for BCR-ABL, 19, 20 and this may occur following chemotherapy-induced PBSC mobilisation.
11 Such transcriptionally silent cells will be unaffected by antisense ODN directed against BCR-ABL mRNA.
Parallel studies of BCR-ABL mRNA and protein levels on the present clinical purges would be helpful in resolving these questions. Unfortunately, after CD34 selection, too few spare cells were available for further experimentation, being at a premium for clinical transplantation. However, extensive information is available from CML cell lines and primary CML cells from these and other patients, and there is no reason why the findings should differ in the present situation. The time course of downregulation of target mRNA by conventionally linked (eg all-phosphorothioate) and chimeric methylphosphonate-phosphodiester linked antisense ODN appears similar for many different targets. Effects are maximal at 4-8 h, but have worn off by 24 h. 21 The effect at the protein level is, however, highly dependent on the half-life of the target protein. For rapidly turning over proteins such as MYC, impressive downregulation can indeed be achieved, and closely follows that of the mRNA. In contrast, the BCR-ABL protein has a half-life of 40 h or more, and levels are unaffected by ODN, even though a dramatic decrease is achieved at the mRNA level. 21 BCR-ABL may therefore be a particularly difficult oncogene to target with conventional ODN structures.
The transplanted dose of CD34-positive cells was lower than would be desirable for autografting for other disorders. 5 However, after CD34-positive cell selection in CML, a cell dose as low as 2 ϫ 10 5 CD34-positive cells/kg recipient weight may lead to adequate haemopoietic reconstitution, although initial engraftment may be slow, possibly because of relative lack of committed progenitors that contribute to early engraftment. 22 Patient 3 took the longest to engraft, despite receiving the most cells (as assessed by CD34-positive cells and CFU-GM numbers). This is not due to differences in graft viability after thawing (as assessed by Trypan Blue exclusion), previous treatment, marrow fibrosis, or intercurrent viral infection post transplantation.
Adequate neutrophil engraftment in the present cases was delayed beyond that expected in patients transplanted with unpurged grafts, 4 although we deliberately did not use post-transplant myeloid growth factors, since all patients remained well, and there were no adverse clinical consequences. Platelet engraftment was slow in all three cases, although four of 18 cases in a recent report of unpurged autografts also took at least 111 days to achieve platelet engraftment, with no apparent relationship with the transplanted cell dose. 4 Similar clinical outcomes have been reported in unpurged autografts using cells harvested during the recovery phase after chemotherapy. [5] [6] [7] In these studies, even if patients are transplanted with exclusively Ph-negative cells, evidence of persisting disease is evident cytogenetically in almost all patients within 12 months of BMT. The present three cases all remained 100% Ph positive following multiple rounds of intensive chemotherapy, and were at least 19 months from original diagnosis; they may therefore represent a group of patients who may fare less well after autografting.
The origin of the cells leading to relapse after autografting for CML is not clear. Residual leukaemic cells in the host which survive conditioning can contribute, since relapse is seen in about 10% of allograft recipients, despite so-called myeloablative therapy which includes total body irradiation. Gene marking studies have suggested that transplanted Ph-positive cells are also important in contributing to relapse, 23 although the relevance of this to the antisensepurged situation is not known.
In summary, the present use of SL-O to facilitate cytosolic ODN delivery appears to be without significant clinically relevant toxicity, and may be of use in applying in vitro progress in antisense design to the treatment of patients with CML.
